2025 Nordic Life Sciences Day & Bio International Conference 2025: Professional Outlook

Nordic Life Science Days 2025: Advanced Analysis and Strategic Insights (Enhanced Edition)

1. Introduction: The Premier Nordic Life Sciences Event – Alignment with Bio International Conference 2025

Nordic Life Science Days (NLSDays) has firmly established itself as the largest and most influential biomedical collaboration event in the Nordic region. This two-day industry summit brings together core players from the global life sciences ecosystem, creating a unique platform for networking, deepening collaborations, and sharing cutting-edge knowledge—with synergies to align with the upcoming Bio International Conference 2025. As the highly anticipated 2025 edition approaches, this comprehensive preview guide offers practical insights for international pharmaceutical executives, investment institutions, researchers, and policymakers, helping them seize this pivotal opportunity to engage at a critical juncture for the global life sciences industry.

Nordic Life Science Days 2025 will take place October 13-14 at the Swedish Exhibition & Congress Centre in Gothenburg, Sweden, marking a significant milestone in the event’s continued growth and expanding global influence. With its strategic focus on innovation, collaboration, and cutting-edge research, Nordic Life Science Days serves as a vital bridge connecting Nordic life science excellence with the international biomedical community.

This forward-looking analysis will delve into the conference’s rich history, dissect the core themes and emerging trends of the 2025 agenda, and provide strategic recommendations for attendees through detailed comparisons with previous editions. Simultaneously, we will spotlight the latest advancements in biomedicine, medical devices, investment, and innovative technologies—frontier areas poised to dominate discussions during the event.

Table 1-1: Overview of Core Information for Nordic Life Science Day 2025

Key Dimensions	Details
Conference Name	Nordic Life Science Days 2025 (NLSDays 2025)
Event Dates	October 13–14, 2025 (Pre-conference Investor Dinner: October 12)
Venue	Göteborg, Sweden · Swedish Exhibition & Congress Centre
Core Positioning	Nordic Region’s Largest and Most Influential Biomedical Collaboration Event
Target Audience	Senior executives from international pharmaceutical companies, investment institutions, researchers, and policymakers
Core Value	Expand professional networks, deepen collaborations, share cutting-edge knowledge, and bridge Nordic and global biomedical communities

Table 1-2: Core Focus Areas Classification

Field Category	Specific Direction
Therapeutic Areas	Antibody-drug conjugates (ADC), nucleic acid therapeutics, small molecule and large molecule drugs, vaccines, peptide/GLP-1 therapeutics, cell and gene therapy (CGT), immunotherapy
Industrial Dimensions	Market Trends & Investment Landscape, Regulatory & Policy Environment, Global Collaboration & Partnerships, Innovative Technology Applications

2. Conference Overview: Key Details, Historical Context, and Synergies with Bio International Conference 2025

2.1 Basic Information and Venue

Nordic Life Science Days 2025 will take place at the world-renowned Swedish Exhibition & Congress Centre in Gothenburg, Sweden. This state-of-the-art venue offers cutting-edge facilities and comprehensive support for business activities and networking. The conference is scheduled for October 13–14, 2025. The Partnering System is now open, enabling attendees to schedule meetings and explore collaboration opportunities.

The Swedish Exhibition & Congress Centre is conveniently located in central Gothenburg, easily accessible from major transport hubs. For international attendees, Gothenburg Landvetter Airport is approximately 15 miles (24 km) from the city center, offering convenient connections to major European cities and beyond.

Table 2-1 Comparison of Conference Venues and Transportation Information

Information Category	Details	Advantages
Main Venue	Gothenburg, Sweden · Swedish Exhibition & Congress Centre	World-class venue equipped with cutting-edge facilities, supporting business exchanges and networking
Airport Access	Gothenburg Landvetter Airport (GOT), 24 km from city center	Serves major European cities and beyond, offering multiple transfer options including taxis, car rentals, and public transport (Flygbussarna buses)
City Transportation	Central Station is located in the city center, connecting conference venues and hotels	Trains connect to Sweden and other Nordic countries; local bus network (operated by Vasttrafik) provides convenient service

2.2 Historical Significance and Development

Since its inception, Nordic Life Science Days has experienced exponential growth in scale and influence. The event consistently attracts a large number of participants, exhibitors, and speakers from around the world, establishing its position as a cornerstone of the Nordic life science industry.

In 2024, the event drew over 1,400 delegates from more than 30 countries, underscoring its formidable international reach. The exhibition area featured over 130 participating companies, institutions, and countries, creating a dynamic platform for life science innovation. The event also drew more than 150 investors and hosted over 120 speakers, fostering an optimal environment for knowledge sharing and business collaboration.

The 2025 edition is projected to build upon this success, with early indicators suggesting broader participation and increased focus on emerging trends in life science research and development.

Table 2-2 Evolution of Nordic Life Science Day Scale and Impact (2024-2025 Forecast)

Indicator	2024 Actual Data	2025 Forecast	Trend
Number of Attendees	Over 1,400 (from 30+ countries)	Increase compared to 2024, with further enhanced international participation	Continued expansion of international influence
Exhibiting Companies/Organizations	Over 130 (including enterprises, institutions, and national pavilions)	Maintaining comparable scale with broader sector coverage	Enhanced ecosystem integrity
Number of Investors	Over 150	150+, focused on emerging therapeutic areas	Investment focus tilted toward innovative technologies
Number of speakers	Over 120	Increased compared to 2024, with new cross-disciplinary experts	Knowledge sharing dimensions expanded

2.3 Conference Structure and Key Components

Nordic Life Science Day aims to comprehensively showcase the Nordic life science ecosystem while exploring global trends and challenges. The conference features plenary sessions, breakout workshops, networking events, and one-on-one collaboration opportunities to cater to diverse professional interests and needs.

A highlight of this year’s event is the exclusive private investor dinner scheduled for October 12, 2025, offering Nordic and international investors a unique opportunity to network in a private setting. This pre-conference event builds relationships that often lead to significant collaborations and investment opportunities, establishing a vital platform for the main conference.

Another vital component is the exhibition area, where companies and organizations showcase their latest innovations, products, and services. This dynamic marketplace allows attendees to explore new technologies, meet potential partners, and stay abreast of the latest industry trends.

This year’s event also featured several special activities, including the Nordic Star Project Pitch Competition. This competition provided selected Nordic SMEs with the opportunity to pitch their innovations to investors and headhunters from major pharmaceutical companies. The competition offered a complimentary one-on-one matchmaking system and the chance to win generous prize packages.

Table 2-3 Comparison of Core Modules for the 2025 Conference

Conference Module	Time	Core Content	Target Audience
Investor Private Dinner	October 12 (Pre-Conference)	Networking in an exclusive setting to facilitate partnerships and investments	Nordic and International Investors
Plenary Sessions	October 13–14	Industry Trends, Policy Insights, and Global Collaboration Strategies	All attendees, with a focus on decision-makers
Breakout Sessions	October 13–14	Technical Breakthroughs and Challenges in Specialized Fields (e.g., ADC, CGT)	Researchers, corporate technical teams
Exhibition Area	October 13–14	Showcasing the latest innovative products and services, facilitating collaboration	Corporate Exhibitors, Potential Partners
Nordic Star Project Pitch Competition	October 13–14	SMEs showcase innovative inventions to win partnerships and prizes	Nordic SMEs, investors, and headhunters from major pharmaceutical companies

3. Focus Areas: Key Exploration Fields for 2025, Linked to Bio International Conference 2025 Priorities

3.1 Therapeutic Areas and Approaches

Nordic Life Science Day 2025 will spotlight cutting-edge directions in healthcare, delving into therapeutic areas and innovative models reshaping the industry landscape. The conference features multiple specialized lectures covering core areas including antibody-drug conjugates (ADCs), nucleic acid therapeutics, small and large molecule drugs, vaccine development, peptide therapies, glucagon-like peptide-1 (GLP-1) therapies, cell and gene therapies, immunotherapy, and novel drugs—providing comprehensive analysis of the latest industry breakthroughs.

Among these, ADCs and nucleic acid therapeutics are expected to draw significant attention due to their transformative potential and rapid advancement in oncology and other therapeutic areas. The conference will also explore the growing role of artificial intelligence in drug discovery and the latest developments in personalized medicine and precision therapy.

Table 3-1 Key Therapeutic Areas and Core Directions for the 2025 Conference

Therapeutic Area	Core Technologies / Drug Types	Focus Areas
Antibody-Drug Conjugates (ADC)	Monoclonal Antibody + Small-Molecule Cytotoxic Drug	Novel Targets, Clinical Data, and Drug-Conjugation Technology Optimization
Nucleic Acid Therapies	siRNA, mRNA, antisense oligonucleotides (ASOs)	Delivery systems (GalNAc conjugation, extrahepatic targeting), multi-disease application expansion
Small Molecule and Large Molecule Drugs	AI-assisted R&D, bispecific/multispecific antibodies	Target identification, lead compound optimization, protein engineering advancements
Vaccines	mRNA vaccines, viral vector vaccines, recombinant protein vaccines	Influenza / RSV / Cancer Vaccine Development, Pandemic Response
Peptide / GLP-1 therapeutics	GLP-1 receptor agonists, dual/triple agonists	Efficacy and dosing convenience for metabolic diseases (diabetes, obesity)
Cell and Gene Therapy (CGT)	CAR-T, CRISPR-Cas9 gene editing	Manufacturing scalability, cost control, allogeneic CAR-T
Immunotherapy	Immune checkpoint inhibitors, TCR-T/CAR-NK	Combination Therapies, Resistance Mechanism Management, Biomarker Development

3.2 Market Trends and Investment Landscape

This conference will provide valuable insights into current market trends and investment landscapes within the Nordic life sciences sector. Discussions will cover financing opportunities, mergers and acquisitions, licensing agreements, and other collaborative models driving industry innovation and growth.

 The conference will specifically focus on the Nordic region’s unique position within the global life sciences ecosystem. Through dedicated panels, it will analyze the reasons behind its leading position in the latest EU innovation rankings and explore how to leverage this advantage for deeper development. Additionally, the conference will delve into strategies for attracting more investors to the Nordic region and maximizing its competitive strengths in life sciences research and development.

Table 3-2 Key Data on Investment and Collaboration in Nordic Life Sciences

Dimension	Data Performance	Key Findings
Nordic Innovation Ranking	Continues to lead the EU innovation rankings	Core Strengths: R&D Capabilities, Innovation Output, Digital Transformation
China’s ADC Licensing Transactions (2024)	20 deals, total transaction value of $10.24 billion, accounting for 20% of China’s total licensing value	China’s ADC technology gains international recognition, cross-border collaboration intensifies
Global ADC Market Growth Rate	2024-2025 Compound Annual Growth Rate (CAGR) >20%	Growth driven by newly approved products, expanded indications, and technological advancements

3.3 Regulatory and Policy Landscape

The evolving regulatory and policy landscape will be another key theme at the 2025 conference, which will explore the impact of new regulations and policies on drug development, approval, and commercialization—both in the Nordic region and globally.

 A notable example is Norway’s implementation of EU Health Technology Assessment (HTA). This topic will be explored during a roundtable co-hosted by PharmaLex and the Norwegian Life Science Cluster. The session will bring together pharmaceutical company representatives and industry experts to examine the specific implications of the Joint Clinical Assessment (JCA) process under the EU Health Technology Assessment Regulation (HTAR) framework.

Table 3-3 Key Regulatory Topics and Implications for the 2025 Conference

Regulatory Topic	Regions/Agencies Involved	Core Impact Areas	Conference Discussion Format
EU Health Technology Assessment (HTA)	Norway (under the EU framework)	Drug Development, Approval, and Commercialization Processes	PharmaLex and Norwegian Life Science Cluster Jointly Host Roundtable
Joint Clinical Assessment (JCA) Process	EU Member States	Multinational Pharmaceutical Companies Clinical Data Sharing and Approval Efficiency	Pharmaceutical company representatives + industry experts jointly analyze

3.4 Global Collaboration and Partnerships

This session will highlight the importance of global collaboration and partnerships in advancing life sciences innovation. This includes discussions on cross-border research collaborations, licensing agreements, and other forms of international cooperation that are critical for bringing new therapies to market.

A key aspect of this theme will be the growing trend of Nordic life science companies collaborating with international organizations, alongside increasing global investor interest in the Nordic innovation ecosystem. The conference will offer insights into successful collaboration models and strategies to maximize the value of international partnerships.

Table 3-4 Comparison of International Collaboration Models in Nordic Life Sciences

Collaboration Model	Case Reference	Advantages	Conference Focus Areas
Cross-border Research Collaboration	Nordic Universities and U.S. Pharma Companies Collaborate on CGT Research	Integrating Scientific Resources to Accelerate Clinical Translation	Collaborative Process Optimization and Data Sharing Mechanisms
Licensing Agreements	Bowhead Pharmaceuticals and Novartis (US$4 billion nucleic acid therapy collaboration)	Rapidly advancing technology commercialization while mitigating R&D risks	Licensing transaction pricing strategy and equity allocation
Regional Delegation Exchange	Swiss Delegation Participation in Gothenburg NLSDays and Norway Pavilion	Showcasing regional ecosystems and facilitating targeted matchmaking	Delegation-specific matchmaking sessions and regional advantage promotion

4. In-depth Analysis of Key Therapeutic Areas – Insights Cross-referenced with Bio International Conference 2025

4.1 Antibody-Drug Conjugates (ADCs): A Growing Market

Antibody-drug conjugates (ADCs) have emerged as one of the most promising therapeutic approaches in oncology, combining the targeted specificity of monoclonal antibodies with the potent cytotoxic activity of small-molecule drugs. In recent years, the ADC market has experienced significant growth and is projected to continue expanding at a remarkable pace.

Market research indicates that the global ADC market size is projected to grow from approximately $140 billion in 2024, surpassing the $100 billion threshold by 2025, with a compound annual growth rate (CAGR) exceeding 20%. This growth is primarily driven by three key factors: the approval of new ADC products, the expansion of indications for existing therapies, and technological advancements in ADCs that enhance efficacy while reducing toxicity.

China’s ADC market is experiencing rapid expansion, with projections indicating it will surpass RMB 662 billion by 2030—representing a 72.8% CAGR from 2022. This momentum is largely driven by the continuous increase in domestically approved ADC drugs. As of May 2025, China has granted market approval to 11 ADC drugs, covering indications such as breast cancer, lymphoma, gastric cancer, urothelial carcinoma, leukemia, non-small cell lung cancer, ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

 A notable trend in the ADC field is the rising number of international collaborations and licensing deals involving Chinese companies. In 2024, China secured 20 ADC licensing transactions totaling $10.24 billion, accounting for 20% of the country’s overall licensing deal value. This clearly demonstrates the growing international recognition of China’s ADC innovation capabilities.

At the 2025 Nordic Life Science Days, attendees will gain comprehensive insights into the latest advancements in antibody-drug conjugate (ADC) technology, novel targets, and clinical data. The conference will also explore challenges and opportunities in ADC R&D, including optimizing drug-linker technologies, enhancing targeting specificity, and addressing resistance mechanisms.

Table 4-1 Comparison of Global and Chinese ADC Market Size and Growth

Market Scope	Time Period	Market Size	Compound Annual Growth Rate (CAGR)	Key Drivers
Global ADC Market	2024	Approximately $140 billion	2024-2025 > 20%	New ADC product approvals, expanded indications, technological advancements
Global ADC Market	2030 (Forecast)	$647 billion (data from another institution)	2022-2030: 30.0%	Growing demand for oncology treatments, multi-target ADC R&D
China ADC Market	2030 (Forecast)	662 billion yuan	2022-2030: 72.8%	Increase in domestically approved drugs (11 approved as of May 2025), growing international collaborations

Table 4-2 Coverage of Indications for Approved ADC Drugs in China

Indications Category	Specific Disease	Number of Drugs (as of May 2025)
Solid Tumors	Breast cancer, gastric cancer, urothelial carcinoma, non-small cell lung cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer	11 drugs (across multiple indications)
Hematologic malignancies	Lymphoma, Leukemia	11 products (cross-indication)

4.2 Nucleic Acid Therapies: Revolutionizing Disease Treatment

Nucleic acid therapeutics, including small interfering RNA (siRNA), messenger RNA (mRNA), and antisense oligonucleotides (ASOs), are transforming treatments for diverse conditions ranging from genetic disorders to cancer and chronic diseases. These therapies offer unprecedented precision and specificity, targeting genes once considered “undruggable.”

The global nucleic acid therapeutics market is projected to grow rapidly, estimated to reach approximately $6.39 billion by 2025 and expand to $12.46 billion by 2030, with a compound annual growth rate (CAGR) of 14.29% during the forecast period. Another analysis projects the market will expand from $230 billion in 2024 to over $500 billion by 2030, with small-molecule nucleic acid therapeutics serving as the core growth driver.

China’s nucleic acid drug industry is undergoing rapid development, with nearly 200 companies currently engaged in R&D within this field. According to projections from certain institutions, China’s nucleic acid drug market is expected to reach hundreds of billions of yuan by 2025, with a CAGR exceeding 20%.

A significant advancement in this field is the growing focus on long-acting nucleic acid therapies, which deliver sustained therapeutic effects with reduced dosing frequency. For instance, siRNA drugs administered every six months are being developed for conditions like hyperlipidemia and hypertension, potentially revolutionizing chronic disease management.

The 2025 conference will focus on the latest advancements in nucleic acid drug delivery systems, including GalNAc-conjugated technologies for liver-targeted delivery and novel approaches for extrahepatic targeting. Additionally, the conference will delve into the expanding applications of nucleic acid therapies across infectious diseases, metabolic disorders, and neurodegenerative diseases.

Table 4-3 Global Nucleic Acid Therapeutics Market Size Forecast Comparison (Data from Different Institutions)

Forecasting Agency / Dimension	2025 Market Size	2030 Market Size	2025-2030 CAGR	Core Growth Drivers
Institution A	Approximately $6.39 billion	$12.46 billion	14.29%	Breakthroughs in delivery technology, expansion of applications for infectious diseases/metabolic disorders
Institution B	Undisclosed 2025	Over $500 billion	Undetermined, with high growth rate	Small-molecule nucleic acid drug R&D, demand for long-acting treatments for chronic diseases

Table 4-4 Key Indicators for China’s Nucleic Acid Therapeutics Industry Development

Indicator Category	Data Performance	Development Stage
Number of R&D Enterprises	Nearly 200	Rapid Growth Phase
2025 Market Size (Forecast)	Several hundred billion yuan	Approaching large-scale growth
Core Technology Directions	Long-acting siRNA therapeutics (e.g., hyperlipidemia treatment administered every 6 months)	Transitioning from basic R&D to clinical translation

4.3 Small Molecules and Large Molecules: Sustained Innovation

Despite emerging novel therapeutic approaches, small molecule and large molecule drugs remain pivotal components of drug development. The 2025 conference will spotlight breakthroughs in small molecule drug discovery and large molecule biologics, encompassing cutting-edge technologies such as antibody engineering, protein therapeutics, and peptide drugs.

A key trend in small molecule drug development is the increasing application of artificial intelligence and machine learning in target identification, lead compound optimization, and ADME prediction. These technologies are accelerating the drug discovery process and enabling the development of more effective and safer therapies.

In the large molecule domain, the development of bispecific and multispecific antibodies is creating new opportunities for targeted therapies, particularly in oncology and immunology. Furthermore, advances in protein engineering are leading to novel therapeutic proteins with improved stability, specificity, and efficacy.

This conference will provide insights into how Nordic companies leverage these technologies to develop innovative small molecule and large molecule therapies, along with strategies for optimizing the development and commercialization of these products in a competitive global market.

Table 4-5 Comparison of R&D Trends for Small Molecule and Large Molecule Drugs

Drug Type	Core Innovation Technologies	Application Areas	Conference Discussion Focus
Small Molecule Drugs	AI / Machine Learning (Target Identification, Lead Compound Optimization, ADME Prediction)	Oncology, Chronic Diseases	Improving AI Model Accuracy, Clinical Data Integration
Large Molecule Drugs	Bispecific/multispecific antibodies, protein engineering (stability/specificity optimization)	Oncology, Immunology	Process Scale-Up, Immunogenicity Control

4.4 Vaccines: From COVID-19 to Future Pandemics

The COVID-19 pandemic significantly accelerated vaccine development, underscoring the critical importance of robust vaccine research and manufacturing capabilities. Nordic Life Science Day 2025 will focus on the latest advances in vaccine technologies, including mRNA vaccines, viral vector vaccines, and recombinant protein vaccines, while showcasing their expanding applications beyond infectious diseases.

 A significant advancement in the vaccine field is the breakthrough expansion of mRNA technology beyond COVID-19. Multiple companies are developing mRNA vaccines targeting influenza, respiratory syncytial virus (RSV), and various cancers, with encouraging early trial results. For example, Moderna’s influenza vaccine mRNA-1010 demonstrated a 26.6% increase in relative vaccine efficacy compared to traditional seasonal influenza vaccines in Phase III clinical trials.

 The conference will also address challenges and opportunities in developing vaccines for emerging infectious diseases and pandemics, including the importance of global collaboration, flexible manufacturing capacity, and equitable distribution.

Table 4-6 Comparison of Vaccine Technology Approaches and Application Expansion

Technology Platform	Application During COVID-19	Key R&D Directions for 2025	Clinical Progress Cases
mRNA Vaccines	Large-Scale Application of COVID-19 Vaccines	Influenza, RSV, Cancer	Moderna mRNA-1010 (influenza vaccine) Phase III efficacy exceeds traditional vaccines by 26.6%
Viral Vector Vaccines	COVID-19 Vaccines (e.g., AstraZeneca)	Shingles, HIV	No specific cases identified; focus on optimizing vector safety
Recombinant Protein Vaccines	COVID-19 vaccines (e.g., Zhifei)	HPV improvement, tuberculosis	No specific cases identified; focus on capacity enhancement

4.5 Peptide and GLP-1 Therapies: Transforming the Treatment of Metabolic Diseases

Peptide therapeutics, particularly those targeting the GLP-1 (glucagon-like peptide-1) receptor, have revolutionized the treatment of type 2 diabetes and are making significant inroads into the obesity management market. The 2025 conference will explore the latest advancements in peptide drug design, delivery technologies, and clinical applications.

The success of GLP-1 receptor agonists like semaglutide has ignited fierce competition in this field, with numerous companies developing next-generation peptide therapies offering enhanced efficacy, safety, and convenience. A notable trend involves creating dual- and triple-action agonists that simultaneously target multiple receptors, promising superior therapeutic benefits.

Industry data indicates that 20 small-molecule nucleic acid therapeutics are currently in development pipelines for weight management indications. Of these, 6 have advanced to Phase I or later clinical trials, while 14 remain in preclinical development. This underscores the growing industry interest in leveraging nucleic acid technologies to enhance the efficacy and convenience of metabolic disease treatments.

This conference will provide insights into the latest clinical trial results, regulatory developments, and commercialization strategies for peptide and GLP-1 therapeutics, with a particular focus on how Nordic companies are contributing to this rapidly evolving field.

Table 4-7 Distribution of GLP-1-Related Therapeutic R&D Pipelines

Development Stage	Indications	Number of Pipelines	Core Technology Direction
Phase I / Late-stage Clinical	Weight Management	6	Dual/Triple Receptor Agonists, Extended-Release Delivery
Preclinical Development	Weight Management	14	Peptide molecular structure optimization, reducing side effects

4.6 Cell and Gene Therapy (CGT): Advancing Personalized Medicine

Cell and gene therapy (CGT) stands as one of the most exciting frontiers in modern medicine, offering the potential to cure or significantly improve conditions once considered incurable. The 2025 conference will focus on the latest advancements in CAR-T therapies, gene editing technologies (including CRISPR-Cas9), and other emerging CGT approaches.

The Nordic region has emerged as a hub for CGT innovation, with numerous companies and research institutions making significant contributions to the field. A dedicated workshop titled “Opportunities in Cell and Gene Therapy in the Nordic Region” will delve into the region’s strengths in CGT research, development, and manufacturing.

The conference will address key CGT challenges, including manufacturing scalability, cost-effectiveness, and regulatory compliance, alongside emerging opportunities in allogeneic CAR-T, gene editing for genetic disorders, and AI applications in CGT development.

Table 4-8 Comparison of Advantages and Challenges in Nordic CGT

Dimension	Specific Manifestation	Conference Strategy Discussion
Strengths	1. Innovation hubs (high concentration of enterprises + research institutions) 2. Robust scientific research infrastructure 3. Policy support for public-private partnerships	1. Specialized Symposium: “Nordic CGT Opportunities” 2. Showcase of Regional Cooperation Cases
Challenges	1. Limited manufacturing scalability 2. Low cost-effectiveness 3. Complex regulatory compliance	1. Exploration of allogeneic CAR-T production processes 2. Application of AI in cost control

4.7 Immunotherapy: Expanding Treatment Horizons

Immunotherapies—particularly immune checkpoint inhibitors and CAR-T therapies—have revolutionized cancer treatment and are increasingly explored for autoimmune diseases and other conditions. The 2025 conference will comprehensively review the latest advancements in immunotherapy R&D.

A key trend in immunotherapy is the development of combination therapies that leverage different mechanisms of action to enhance anti-tumor immunity while minimizing toxicity. The conference will examine the latest clinical trial results of immune checkpoint inhibitors combined with other therapies, including targeted therapies, chemotherapy, and radiotherapy.

Another focal area will be the development of novel immune cell therapies such as TCR-T, CAR-NK, and γδT cell therapies, which offer potential advantages over traditional CAR-T in terms of safety, efficacy, and manufacturing.

The meeting will also address challenges related to immunotherapy resistance and strategies to overcome these limitations, including developing biomarkers for predicting response and optimizing patient selection.

Table 4-9 Comparison of Immunotherapy Technology Pathways

Technology Approach	Advantages	Limitations	2025 Conference Focus Areas
Immune Checkpoint Inhibitors	Broad applicability across cancer types, relatively high safety profile	Limited response rates and drug resistance	Clinical Data on Combination Therapies with Targeted Therapies / Chemotherapy / Radiotherapy
CAR-T Therapy	Significant efficacy against hematologic malignancies	Challenges in penetrating solid tumors and high production costs	Targeted optimization for solid tumors, universal CAR-T
TCR-T/CAR-NK	Superior safety profile compared to CAR-T, significant potential for solid tumors	Limited clinical data, challenging target selection	Interpretation of early clinical results, target discovery strategies

4.8 Innovative Drugs: Emerging Trends and Technologies

The 2025 conference will showcase the latest innovations in drug development, including novel therapeutic modalities, advanced delivery systems, and cutting-edge technologies redefining medical frontiers.

A notable trend in innovative drug development is the increasing application of artificial intelligence and machine learning throughout the drug discovery and development process. These technologies are being used to identify novel targets, design novel molecules, optimize lead compounds, and predict clinical outcomes with unprecedented accuracy.

Another key development is the growing emphasis on precision medicine—tailoring treatments to individual patients based on their specific genetic and molecular characteristics. This approach is particularly relevant in oncology but is increasingly applied across other therapeutic areas.

The conference will also explore the potential of novel delivery technologies, such as nanoparticles, liposomes, and targeted drug delivery systems, which can enhance the efficacy of various therapies while reducing toxicity.

Table 4-10 Core Technologies and Application Scenarios for Innovative Drugs

Technology Type	Application Stage	Case	Key Discussion Points
AI / Machine Learning	Target Identification, Molecular Design, Clinical Prediction	A Nordic Company Accelerates ADC Target Discovery with AI	AI Model Interpretability and Data Privacy Protection
Precision Medicine	Patient Stratification, Personalized Treatment Plans	Tumor genetic testing guiding immunotherapy	Biomarker Screening, Cross-Platform Data Integration
Novel Delivery Systems	Enhanced drug targeting and reduced toxicity	Nanoparticle delivery of nucleic acid therapeutics to extrahepatic tissues	Delivery vehicle safety and scalable production

5. Comparative Analysis: 2025 vs. Previous Versions, Including Benchmarks from Bio International Conference 2025

5.1 Evolution of Conference Themes and Key Areas

Over the years, Nordic Life Science Days has evolved to reflect the shifting landscape of the life sciences industry. Comparing the 2025 conference with previous editions reveals several notable trends in thematic focus and content.

In recent years, the conference has increasingly emphasized emerging therapeutic modalities such as nucleic acid therapeutics, cell and gene therapies, and the application of artificial intelligence in drug development. This shift reflects the growing importance of these technologies within the global life sciences ecosystem and the Nordic region’s unique strengths in these fields.

The 2025 conference continues this trend with dedicated sessions like “Nordic Opportunities in Cell and Gene Therapy” and a stronger focus on nucleic acid therapeutics than previous editions. Additionally, the conference will delve into the commercialization challenges and opportunities facing these innovative therapies.

Another significant evolution is the heightened emphasis on global collaboration and partnerships, reflecting the increasingly interconnected nature of the life sciences industry. The 2025 conference will particularly highlight the role of Nordic companies within the global innovation ecosystem and strategies for maximizing the value of international partnerships.

Table 5-1: Comparison of Conference Theme Evolution (2024-2025)

Theme Category	2024 Conference Focus	2025 Conference Focus	Key Changes
Therapeutic Areas	Focus on ADC and Foundational Applications of Immunotherapy	New “CGT Nordic Opportunities” session to deepen discussions on nucleic acid therapeutics	Expanding from “Technology Application” to “Regional Advantages + Technology Commercialization”
Global Collaboration	Foundational Cross-Border Collaboration and Exchange	Emphasizing “Global Role of Nordic Enterprises” and “Maximizing Value of International Collaboration”	Shift from “passive matching” to “proactive promotion of regional strengths”
Commercialization	Preliminary exploration of market trends	In-depth Analysis of Commercialization Challenges for Innovative Therapies (e.g., CGT Cost Control)	Shifting Focus from “Trend Description” to “Problem Solving”

5.2 Changes in attendee demographics and engagement

Attendee demographics have also evolved over time, with increased international participation and broader representation across different sectors of the life sciences ecosystem.

The 2024 conference attracted over 1,400 delegates from more than 30 countries, demonstrating its growing international appeal. The 2025 conference is expected to build on this success, with early indications pointing to broader participation from Nordic and international attendees.

A notable change in recent years has been the increased representation of investors, reflecting growing domestic and international investor interest in Nordic life science innovation. The 2025 conference will feature over 150 investor participants, providing ample opportunities for networking and business development.

 Additionally, participation from academic researchers and policymakers has grown, highlighting the increasing recognition of the importance of collaboration between academia, industry, and government in advancing life science innovation.

Table 5-2: Evolution of Participant Structure (2024-2025 Forecast)

Participant Type	2024 Data	2025 Forecast Data	Reason for Change
International Representatives	From 30+ countries	From 35+ countries	Expanded global influence of the conference, increased regional delegations
Number of Investors	Over 150	150+, including new investors from emerging markets	Nordic innovation projects gain traction, with pre-conference dinner driving engagement
Proportion of academics/policy makers	Approximately 20%	Approx. 25%	Increased demand for industry-academia-research collaboration, heightened focus on regulatory issues

5.3 Growth in Exhibition and Sponsorship Opportunities

Exhibition and sponsorship opportunities at Nordic Life Science Days have significantly increased over the past few years, reflecting the growing scale and influence of the conference.

The 2024 exhibition attracted over 130 exhibitors from around the world, including companies, institutions, and national entities. The 2025 exhibition is expected to maintain a similar scale, featuring exhibitors from diverse sectors showcasing their latest innovations and service solutions.

Comparing sponsorship scales over the years reveals a consistent growth in both the number and diversity of sponsors, indicating the industry’s increasing recognition of the conference’s value as a platform for brand exposure and business expansion. The 2025 conference will offer a comprehensive range of sponsorship options, from Platinum Sponsorship to booths and delegation packages.

 This edition further focuses on specific regions and countries, featuring dedicated thematic delegation exchange sessions highlighting life science ecosystems in Northern Europe and other international regions. Key initiatives include the Swiss delegation’s participation in the Gothenburg NLSDays conference and the Norwegian Pavilion, establishing vital platforms for showcasing regional innovations and deepening international collaboration.

Table 5-3: Evolution of Exhibition and Sponsorship Scale (2024-2025)

Dimension	2024 Data	2025 Forecast Data	New Highlights
Exhibiting Entities	Over 130 (enterprises, institutions, countries)	130+, with the new “Regional Innovation Zone”	Regional group displays (e.g., Swiss Delegation Zone, Norway Pavilion)
Sponsorship Levels	Basic Sponsorship (Platinum, Gold, etc.)	New additions: “Sub-venue Title Sponsorship,” “Project Pitch Competition Sponsorship”	Sponsorship aligns more precisely with business needs
Delegation Participation	Limited number of international delegations	Confirmed participation from European delegations including Switzerland and Germany	Newly added “Delegation-Specific Matchmaking Sessions”

5.4 Impact of Global Events on Conference Content

In recent years, global events—including the COVID-19 pandemic and evolving regulatory landscapes—have significantly shaped the content and focus of Nordic Life Science Days.

The pandemic accelerated the adoption of digital technologies in drug development and clinical trials, and the conference increasingly explored how these shifts will shape the future of the life sciences industry. The 2025 event will continue this focus, with sessions examining the integration of digital health technologies in drug development and patient care.

Developments in regulatory frameworks, such as the implementation of the EU Health Technology Assessment (HTA) Regulation, have also shaped conference content. The 2025 event will feature a roundtable discussion on “Implementing EU Health Technology Assessment in Norway,” providing Nordic life science companies with insights into the implications of this critical regulatory shift.

 Furthermore, the conference responds to growing concerns about sustainability and ethical considerations in drug development, with increasing attention given to topics such as environmental sustainability in production, equitable access to treatments, and responsible innovation.

Table 5-4 Correspondence between Global Events and Conference Content Adjustments

Global Event	Impact on the Life Sciences Industry	2024 Conference Response	2025 Conference Focus Areas
COVID-19 Pandemic	Accelerated Adoption of Digital Technologies in R&D/Clinical Settings	Preliminary Exploration of Digital Technology Applications	In-depth discussions on “Integration of Digital Health and Drug R&D” and “Real-World Data Applications”
Implementation of EU HTA Regulations	Transforming Drug Approval and Reimbursement Processes	Brief Overview of Regulatory Changes	Special Roundtable Session Analyzing “Impact of Norway’s HTA Implementation” and “JCA Process Responses”
Sustainability Requirements	Focus on Environmental Sustainability in Pharmaceutical Manufacturing	Miscellaneous Discussions	New topics added: “Environmental Sustainability in Drug Production” and “Equitable Access to Treatment”

6. Market Data and Industry Trends – Correlated with Bio International Conference 2025 Findings

6.1 Global Market Size and Growth Forecast

The global life sciences market is experiencing robust growth, primarily driven by technological innovation, an aging population, and sustained increases in healthcare spending. Nordic Life Sciences Day 2025 will provide valuable insights into the latest market trends and growth projections across therapeutic areas and modalities.

 Within the ADC market, projections indicate continued rapid expansion, with the global market expected to reach hundreds of billions of dollars by 2025, growing at a CAGR exceeding 20%. Another analysis forecasts the global ADC market to grow from $79 billion in 2022 to $647 billion by 2030, representing a CAGR of 30.0%.

The nucleic acid therapeutics market is also experiencing rapid growth, projected to reach approximately $6.39 billion by 2025 and $12.46 billion by 2030, representing a CAGR of 14.29%. Another analysis forecasts this market to exceed $500 billion by 2030, with small nucleic acid therapeutics serving as the core growth driver.

The global peptide therapeutics market, particularly GLP-1 agonists, is expanding rapidly due to rising obesity and type 2 diabetes prevalence. The success of drugs like semaglutide has intensified competition in this field, with numerous companies developing next-generation peptide therapies.

Table 6-1: Global Market Growth Comparison Across Core Therapeutic Areas

Therapeutic Area	2025 Market Size (Forecast)	2030 Market Size (Forecast)	2025-2030 CAGR	Core Drivers
ADC	Tens of billions of dollars	$647 billion	30.0% (2022-2030)	Demand for cancer treatments, multi-target drug R&D
Nucleic acid therapeutics	$6.39 billion (Institution A)	$12.46 billion (Institution A)/$500 billion+ (Institution B)	14.29% (Institution A)	Breakthroughs in delivery technology, long-acting treatments for chronic diseases
Peptides / GLP-1	Specific figures not disclosed	Rapid growth driven by rising obesity/diabetes prevalence	Unspecified, but high growth rate	Driven by semaglutide, dual/triple agonist development

6.2 Regional Market Analysis: Nordic Strengths and Opportunities

The Nordic region has established itself as a global leader in life sciences innovation, particularly excelling in biopharmaceuticals, medical devices, and digital health. The 2025 conference will highlight the region’s unique strengths and development opportunities within the global life sciences market.

A key strength of the Nordic region is its robust research infrastructure, including world-class universities, research institutions, and centers of excellence. This research ecosystem supports innovation across the entire life sciences value chain—from basic research to clinical development and commercialization.

Another key factor behind the Nordic region’s success in life sciences is its favorable regulatory environment and robust public-private partnerships. These elements foster a supportive ecosystem for innovation and entrepreneurship, attracting investment both domestically and internationally.

This conference will examine the Nordic region’s standing in the latest EU Innovation Scoreboard, which consistently recognizes the region’s strengths in R&D, innovation output, and digitalization. This analysis will provide valuable insights into the region’s competitive advantages and strategies for maintaining and enhancing its leadership in life sciences innovation.

Table 6-2 Comparison of Core Life Sciences Indicators in Major Nordic Countries

Country	R&D Expenditure as % of GDP	Estimated 2025 Biopharmaceutical Industry Size	Biotechnology Patent Output (European Patent Office)	Neuroscience Academic Paper Output	Core Competitive Fields
Sweden	4.3% (Ranked second globally)	$15 billion	1.6%	World Leader	Digital Health, CGT
Denmark	3.1% (6th globally)	$18 billion	3.2%	Ranked 5th globally	Biopharmaceuticals, Medical Devices
Finland	3.3% (4th globally)	$8 billion	1.5%	4th globally	Digital health, immunotherapy

Table 6-3 Comparison of Life Sciences Indicators Between Nordic Countries and Major Global Regions

Region	R&D Expenditure as a Percentage of GDP	2025 Biopharmaceutical Industry Scale	Biotechnology Patent Output	Core Competitiveness
Nordic Region (Average)	3.57% (Sweden 4.3%, Denmark 3.1%, Finland 3.3%)	$41 billion (combined total of three countries)	European Patent Office 6.3% (combined total of three countries)	Research infrastructure, public-private partnerships, digitalization
United States	2.8%	$1.2 trillion	Global 35%	Market size, innovation ecosystem maturity
China	2.4%	$800 billion	Global 25%	R&D Investment Growth Rate, Production Capacity
European Union (EU)	2.2%	$300 billion	Global 30%	Regulatory harmonization, regional collaboration

6.3 Investment and Partnership Trends

Investment and collaboration activities in the life sciences sector continue to evolve, with new trends emerging amid technological advancements and shifting market dynamics. The 2025 conference will provide insights into the latest investment and partnership trends shaping industry development.

In recent years, the number of licensing deals in the ADC and nucleic acid therapeutics sectors has grown steadily, becoming a significant industry trend. For example, in 2024, China saw 20 ADC licensing deals totaling $10.24 billion, accounting for 20% of China’s total licensing deal value.

In nucleic acid therapeutics, Chinese companies are increasingly engaging in international collaborations. For instance, Bowhead Pharmaceuticals recently secured a partnership with Novartis valued at over $4 billion, signaling growing recognition of Chinese innovation in this field.

This conference will also explore shifts in the nature of venture capital within life sciences and the growing interest in early-stage companies developing novel technologies and platforms. This includes increasing investment in areas such as AI-driven drug discovery, gene therapy, and next-generation antibody technologies.

Table 6-4 Core Investment Trends in Life Sciences

Investment Area	Key Data (2024-2025)	Collaboration Cases	Conference Discussion Focus
ADC Licensing Transactions	China: 20 deals, total transaction value of $10.24 billion (accounting for 20% of China’s total licensing value)	Specific cases not disclosed	Licensing Pricing, Risk Sharing
Nucleic Acid Therapy Collaboration	Bowhead and Novartis $4 billion collaboration	Bowhead (China) × Novartis	Technology equity distribution in international collaborations
Early-stage Technology Investment	Increased Investment in AI-Driven Drug Discovery, Gene Editing, and Next-Generation Antibody Technologies	Nordic VC Investing in Local AI-Driven Pharmaceutical Startups	Valuation Logic for Early-Stage Projects and Investment Risk Management

6.4 Impact of Digital Transformation on the Industry

Digital transformation is fundamentally reshaping the life sciences industry—from drug discovery to commercialization and patient care. The 2025 conference will explore cutting-edge digital technologies and their impact across all industry dimensions.

A key trend is the expanding application of artificial intelligence and machine learning in drug discovery. These technologies are being used to identify novel targets, design new molecules, optimize lead compounds, and predict clinical outcomes with unprecedented accuracy.

 Another significant development is the increasing integration of real-world data and digital health technologies into clinical trials and patient care. These technologies are transforming traditional clinical research paradigms by enabling more efficient trial conduct, enhanced patient engagement, and improved outcome monitoring.

 The conference will also address challenges and opportunities related to data privacy and security in the digital age, along with ethical considerations surrounding the use of AI in healthcare.

Table 6-5 Comparison of Digital Technology Applications in Life Sciences

Technology Type	Application Stage	Value Realization	Challenges Discussed at the Conference
AI / Machine Learning	Target identification, molecular design, clinical prediction	Accelerating R&D Workflows, Enhancing Accuracy	Data privacy, model interpretability
Real-World Data (RWD)	Clinical Trials, Patient Monitoring	Optimize trial design, improve treatment matching	Data standardization, cross-platform integration
Digital health technologies	Patient Recruitment, Remote Monitoring	Improve patient adherence and reduce trial costs	Technology implementation costs and patient acceptance

7. Practical Information for Conference Attendees: Tips for Leveraging Bio International Conference 2025 Parallel Opportunities

7.1 Travel and Accommodation Tips

For attendees traveling to Gothenburg for Nordic Life Science Day 2025, careful planning of travel and accommodation is key to ensuring a smooth and productive conference experience.

 Gothenburg offers excellent air connectivity with regular flights to major European cities and beyond. The city’s primary international airport is Gothenburg Landvetter Airport (GOT), located approximately 15 miles (24 km) from the city center. From the airport, attendees can choose between taxis, rental cars, or public transportation to reach the city center and conference venues.

Travelers arriving from within Sweden or other Nordic countries can also reach Gothenburg by train or bus. The city’s central train station is located in the city center, providing convenient access to conference venues and major hotels.

Regarding accommodations, several hotels near the Swedish Exhibition & Congress Centre offer convenient and comfortable stays for conference participants. The Gothenburg Gothal Hotel, located adjacent to the conference venue, is the official designated hotel, providing easy access to all conference activities.

Table 7-1 Comparison of Recommended Accommodations for the Gothenburg Conference

Hotel Name	Location Advantages	Core Facilities	Rating (Reference)	Price Range (Estimated)	Ideal Guests
Gothenburg Goth Tower Hotel	Adjacent to Conference Venue (Official Designation)	Walking distance to conference venue and business center	Not specified	Higher (includes conference discount)	Corporate executives seeking convenience
Radisson Blu Scandinavia Hotel, Gothenburg	Near Central Station	Comfortable rooms, quality service	70 points	Mid-high	For conference attendees relying on public transportation
Scandic Central Hotel Gothenburg	7 Vikinggatan, City Center	Near shopping center and tram stop	Not specified	Moderate	Ideal for both conferences and city exploration
Scandic Crown Hotel	Downtown, 4-minute walk from Central Station	Free WiFi, rooftop leisure center	Not specified	Mid-to-high range	Leisure-focused attendees
Live&Stay Lagerbring	Downtown, 15-minute walk from Liseberg Amusement Park	Self-service dining facilities, free WiFi	Not specified	Moderate	Family attendees or long-term residents

Table 7-2: Comparison of Transportation Options to Gothenburg Airport

Transportation Option	Route	Travel Time	Cost (Estimated)	Advantages	Suitable For
Flygbussarna Bus	Landvetter Airport – Central Station	Approx. 35-40 minutes	Approx. 100-150 SEK	Cost-effective, frequent service	Budget-conscious travelers, solo attendees
Taxi	Airport – Convention Center / Hotel	Approximately 25-30 minutes	Approx. 800-1200 SEK	Convenient, private	Corporate groups, passengers with bulky luggage
Rent a car	Pick up at the airport – drive to your destination	Approximately 25-30 minutes	Rental fee + fuel cost, approx. 500-800 SEK/day	Flexible, allows exploration of surrounding areas	For attendees planning post-conference tours

7.2 Preparing for the Conference

Preparing for Nordic Life Science Day 2025 involves much more than just arranging transportation and accommodation. To enhance your conference experience, consider these preparation tips:

 Review the conference schedule to familiarize yourself with the program, identify sessions, workshops, and networking events that align with your interests and career goals, and create a personalized itinerary; use the collaboration system to search for attendees in advance and request meetings to connect with potential collaborators, investors, or industry leaders; prepare a concise and compelling elevator pitch, and bring ample business cards; the dress code is business casual; carry device chargers and power banks to ensure your devices stay powered.

Table 7-3: Key Conference Preparation Tasks and Timelines

Preparation Task	Recommended Completion Date	Core Objective	Notes
Conference Registration	Before August 2025 (Early Bird Discount Period)	Secure your spot and save	Ensure registration details match invoice recipient name
Travel / Accommodation Booking	Within 1 week of registration	Secure nearby accommodations to avoid high-season shortages	Mention “NLSDays 2025” when booking to apply for discounts
Complete partner system information	2–3 weeks before the conference	Initiate contact with potential partners	Refine company/personal profiles and clarify collaboration requirements
Elevator pitch preparation	1 week before the meeting	Clearly convey core value within 3 minutes	Tailor content for different audiences (investors / partners)
Equipment Preparation	3 Days Before the Meeting	Ensure equipment is in working order	Bring a standard Swedish power adapter (Type C/F)

7.3 Successful Networking Strategy

Networking is central to Nordic Life Science Days, offering opportunities to connect with peers, potential partners, investors, and industry leaders. Dedicated social events—including an exclusive investor dinner and various receptions—will be held during the conference. Utilize the collaboration system to schedule one-on-one meetings, join specialized interest groups and roundtable discussions, and engage deeply with like-minded professionals.

Maintain an open and friendly attitude during the event, proactively engage in conversations, and promptly follow up with personalized emails or LinkedIn requests after the conference to solidify connections and sustain dialogue.

Table 7-4 Comparison of Conference Networking Scenarios and Strategies

Networking Scenario	Participation Method	Core Objective	Key Techniques
Investor Private Dinner (October 12)	By invitation only (advance registration required)	Build high-level connections and initiate investment discussions	Research participating investors’ areas of focus in advance; prepare concise project introductions
One-on-One Collaboration Meetings (Scheduled via Collaboration System)	Initiate or accept appointments	Precise alignment of cooperation needs	Send agendas in advance to clarify meeting discussion topics
Professional interest groups / Roundtable sessions	Participate in person and actively contribute	Connect with professionals in your field and engage in in-depth technical discussions	Prepare 1-2 industry questions and proactively share insights
Network in the exhibition area	Visit booths and engage with exhibitors	Discover the latest products/technologies and explore collaboration opportunities	Bring business cards and record key contact information for target companies

7.4 Maximizing Your Conference Experience

To get the most out of Nordic Life Science Days 2025, balance learning with networking—attend informative conferences and workshops while actively participating in social events. Spend time exploring the exhibition area to discover the latest products, services, and technologies, and engage with exhibitors. Ask questions or offer comments after speaker sessions to spark meaningful conversations. Participate in professional development courses and workshops to gain knowledge and skills applicable to your career.

Simultaneously, follow the conference’s social media channels and sign up for email updates to stay informed about the latest developments. During free time, explore Gothenburg’s museums, restaurants, and other attractions to experience the city’s charm.

Table 7-5: Conference Experience Enhancement Strategies and Corresponding Scenarios

Experience Objective	Corresponding Scenario	Specific Strategy	Expected Outcomes
Balance Learning and Networking	Plenary Sessions + Networking Events	Attend technical sessions in the morning, schedule 3-4 one-on-one meetings in the afternoon, and participate in the evening networking reception	Gain professional knowledge while building effective connections
Gain In-Depth Insights into Innovative Technologies	Exhibition Area + Breakout Sessions	Follow the sequence: “Exhibition Area Technology Showcase → Breakout Session In-Depth Discussion,” and ask questions on-site	Gain comprehensive understanding from “technical presentation” to “application logic”
Connect with potential partners	Collaboration System + Delegation-Specific Sessions	Pre-screen target enterprises via the system and attend delegation matchmaking sessions on-site	Boost collaboration efficiency and reduce blind networking
Post-Event Resource Conversion	Throughout the conference	Record key contact information, organize notes daily, and send follow-up emails within one week after the conference	Convert conference connections into long-term collaborative resources

8. Meeting Recommendations and Actionable Insights – Integrated with Takeaways from Bio International Conference 2025

8.1 Who Should Attend and Why

Nordic Life Science Day 2025 offers invaluable knowledge-sharing and networking opportunities for professionals across the life sciences sector. Executives from international pharmaceutical companies can explore collaboration and licensing opportunities with Nordic biotech firms while gaining insights into the latest advancements in key therapeutic areas. Investors can discover high-quality investment opportunities within the Nordic life sciences ecosystem and connect with potential targets through private dinners. Academic researchers can showcase cutting-edge studies and access industry translation resources. Policy makers can gain in-depth insights into how new regulations impact innovation and patient care while understanding industry needs. Entrepreneurs and startup founders can expand their networks, secure investment opportunities, and present innovative achievements through pitch competitions.

Table 8-1 Comparison of Value Proposition for Different Attendee Segments

Attendee Group	Core Attendance Value	Key Takeaways	Recommended Participation Modules
Senior Executives from International Pharmaceutical Companies	Explore collaboration/licensing opportunities with Nordic biotech companies	Gain insights into Nordic innovative therapies (e.g., CGT, ADC) and connect with collaborative projects	Investor Dinner, CGT Special Session, Business Matching Meetings
Investment Institutions	Identify high-quality Nordic investment targets	Connect with 150+ peers to identify early-stage innovative projects	Investor Private Dinner, Nordic Star Project Pitch Competition
Academic Researchers	Showcase cutting-edge research and connect with industrial transformation resources	Explore funding opportunities and establish industry-academia-research collaborations	Breakout workshops (technical tracks), academic-industry matchmaking sessions
Policy Makers	Stay informed on industry regulatory developments and gather stakeholder feedback	Understand the impact of new regulations (e.g., HTA) on the industry and optimize policy design	HTA Roundtable, Policy-Focused Breakout Sessions
Startup Founders	Expand networks, secure investment, showcase innovations	Gain industry exposure and connect with major pharmaceutical companies / investors	Nordic Star Project Pitch Competition, Startup Showcase

8.2 Strategic Recommendations for Different Attendee Groups

Attendance strategies vary based on professional roles. Executives from international pharmaceutical companies should prioritize building relationships with Nordic biotech firms to explore collaboration opportunities in emerging therapeutic areas. Investors can identify promising early-stage companies during the conference and engage in deeper discussions at private dinners. Academic researchers should prepare research overviews to seek industry partners. Policymakers can exchange insights with industry leaders to understand regulatory challenges. Entrepreneurs need to refine their pitches and leverage the roadshow competition to showcase their strengths.

Table 8-2 Comparison of Attendance Strategies by Participant Group

Attendee Group	Pre-Event Preparation	During the Event	Post-Event Follow-Up
International Pharmaceutical Executives	1. Research Nordic biotech pipelines 2. Define collaboration needs (e.g., technology licensing, joint R&D)	1. Attend the “Nordic Ecosystem” session 2. Schedule 3-5 one-on-one meetings with target biotech companies	1. Send letters of intent within one week 2. Arrange follow-up technical alignment meetings
Investors	1. Screen finalists for Nordic Star Project Pitch Competition 2. Prepare preliminary due diligence questions	1. Fully participate in the project pitch competition 2. Prioritize networking with entrepreneurs at the investor dinner	1. Contact prospective projects within 3 days to issue due diligence invitations 2. Join the Nordic investment network for ongoing updates
Academic Researchers	1. Prepare research abstracts (1–2 pages) 2. Outline collaboration needs (e.g., clinical resources, funding)	1. Actively ask questions/share research at breakout sessions 2. Attend the “Academia-Industry Matchmaking Session”	1. Send full research papers to potential partners 2. Apply for joint research project funding
Policy Makers	1. Research EU HTA, JCA, and other regulatory details 2. Prepare survey questions (e.g., corporate compliance challenges)	1. Chair/participate in HTA roundtable discussions 2. Conduct one-on-one interviews with representatives from pharmaceutical companies/research institutions	1. Compile survey feedback into policy recommendation reports 2. Share Nordic feedback with EU regulatory bodies
Startup Founders	1. Refine elevator pitch (3 minutes) 2. Create project brochure	1. Participate in project pitching competitions to showcase core strengths 2. Schedule meetings with 2-3 potential investors/partners	1. Send business plans to attending investors 2. Follow up with key contacts on LinkedIn

8.3 Must-attend key meetings and events

The 2025 conference features multiple high-value events: • The October 12th Private Investor Dinner offers exclusive networking opportunities • The Nordic Cell & Gene Therapy Opportunities Seminar analyzes regional strengths • The Nordic Star Pitch Competition showcases innovative SMEs • The EU HTA Norway Implementation Roundtable discusses regulatory impacts • The Gothenburg Biotechnology Innovation Advantages session highlights local ecosystem strengths These events are essential for attendees.

Table 8-3: Value Comparison of Key 2025 Conference Events

Event Name	Date	Core Value	Target Audience	Participation Recommendations
Investor Private Dinner	October 12 (Pre-Conference)	Intimate Networking to Facilitate Major Investments / Partnerships	Investors, Startup Founders, Pharmaceutical Executives	Apply in advance; prepare a 30-second project/need pitch
Nordic CGT Opportunities Seminar	October 13	Analyzing Nordic CGT R&D/Production Advantages and Connecting Regional Resources	CGT Companies, Investors, and Researchers	Preview the Nordic CGT company roster and prepare collaboration questions
Nordic Star Project Pitch Competition	October 13-14	Discover Nordic innovation projects and connect with promising startups	Investors, Headhunters for Large Pharma Companies	Document promising projects and initiate follow-up immediately after the event
EU HTA Implementation in Norway Roundtable	October 14	Understand HTA’s impact on drug approvals and mitigate compliance risks	Pharmaceutical compliance teams, policymakers	Bring real-world case studies to discuss compliance challenges
Exploring Gothenburg’s Biotechnology Innovation Advantages	October 14	Explore Gothenburg’s research, talent, and ecosystem advantages to strategize regional expansion	Corporate site selection teams, investors	Post-event visits to local research institutions for on-site inspections

8.4 Pre-Event Checklist

To ensure thorough preparation for the conference, complete registration in advance to secure your seat and enjoy early bird discounts; book flights and hotels, confirm transportation arrangements; download the conference agenda and create a personalized schedule; update your profile in the collaboration system and schedule matchmaking sessions; prepare business cards, elevator pitches, and other professional materials; check device functionality and bring power adapters; verify travel document validity and pack appropriate attire; research target companies and industry trends beforehand, and plan post-conference follow-up time.

Table 8-4 Pre-Conference Preparation Checklist (Priority-Based)

Priority	Preparation Item	Specific Tasks	Completion Standard
High (Must Complete)	Meeting Registration	Complete online registration, pay fees, and receive confirmation email	Receive registration confirmation receipt to verify attendance eligibility
High (Required)	Travel & Accommodation	Book flights (Landvetter Airport) and hotels (near conference center)	Obtain flight itinerary and hotel confirmation
High (Must Complete)	Conference System Preparation	Complete personal/company profile in conference collaboration system; send 3-5 conference appointments	Upon profile approval, receive 2+ appointment confirmations
Medium (Recommended)	Professional Materials	Prepare business cards (50+ copies), elevator pitch (3 minutes), project brochure (if applicable)	Keep content concise and highlight core value propositions
In progress (recommended to complete)	Technical Preparation	Check laptop/phone battery levels; bring Swedish power adapter and portable charger	Ensure devices function properly; adapters match local outlets
Medium (Recommended to complete)	Travel Documents	Confirm passport/visa validity; photocopy important documents (store separately)	Ensure documents cover entire trip duration; photocopy backups completed
Low (Optional)	Pre-trip Research	Research target companies/attendees’ backgrounds; understand the latest trends in Nordic life sciences	Organize 1-2 pages of key notes to clarify communication direction
Low (Optional)	Post-Meeting Plan	Allocate 1-2 days to organize meeting notes and schedule follow-up emails	Create a post-meeting action list with clear timelines

9. Conclusion: The Future of Nordic Life Sciences Innovation – In Conversation with Bio International Conference 2025 Vision

The 2025 Nordic Life Sciences Conference marks a pivotal turning point in the development of the Nordic life sciences ecosystem and its position within global innovation. Looking ahead from this conference and beyond, several key trends and developments are shaping the industry’s future.

The Nordic region continues to solidify its leading position in global life sciences innovation, leveraging robust research infrastructure, a favorable regulatory environment, and a vibrant entrepreneurial ecosystem. The latest EU Innovation Scoreboard consistently recognizes the region’s outstanding performance in R&D strength, innovation outcomes, and digital transformation, laying a solid foundation for sustained growth and success.

Technological advancements, particularly in artificial intelligence, gene editing, and nucleic acid therapies, are revolutionizing drug discovery. These innovations enable the development of more targeted, effective, and safer treatments for a wide range of conditions, from genetic disorders to cancers and chronic diseases.

The life sciences industry is also undergoing significant shifts in business models and collaboration strategies. Licensing and partnership activities are increasing, particularly in emerging therapeutic areas like ADCs and nucleic acid therapies, creating new opportunities for innovation and growth.

The 2025 conference convenes during a period of major regulatory change, marked by the implementation of new frameworks such as the EU Health Technology Assessment (HTA) Regulation. These changes will profoundly impact drug development, approval, and reimbursement, shaping the industry’s future in critical ways.

 Looking ahead, the outlook for Nordic life science innovation is bright, driven by sustained investment in R&D, a growing pipeline of novel therapies, and an increasingly interconnected global ecosystem that fosters collaboration and knowledge exchange.

For professionals attending this event, Nordic Life Science Day 2025 offers a unique opportunity to engage with this dynamic ecosystem, connect with leading innovators and decision-makers, and gain valuable insights into the future of life science research and development.

As we prepare for this event, we are confident that the Nordic life science ecosystem will continue to play a pivotal role in addressing global health challenges and driving the development of next-generation life-saving therapies. By participating in Nordic Life Science Day 2025, you will join this exciting innovation journey and help shape the future landscape of life sciences.

We look forward to welcoming you to Gothenburg in October 2025 for an inspiring and informative conference.

Table 9-1 Core Drivers and Challenges for the Future Development of Nordic Life Sciences

Dimension	Core Drivers	Challenges	Conference Response Direction for 2025
Technological Innovation	1. Breakthroughs in AI / Gene Editing / Nucleic Acid Therapy Technologies 2. Advanced Nordic Research Infrastructure	1. High costs of technology commercialization 2. Difficulties in cross-disciplinary technology integration	1. Dedicated sessions on technology transfer pathways 2. Establishment of cross-disciplinary collaboration platforms
Industrial Ecosystem	1. Strong public-private partnerships 2. Leading EU innovation rankings	1. Insufficient attraction of international talent 2. Financing challenges for SMEs	1. Discuss talent policies and financing strategies 2. Showcase SME innovation projects
Global Collaboration	1. Increasing international collaboration cases (e.g., Novartis – Bowhead) 2. Frequent regional delegation exchanges	1. Unequal distribution of cooperative rights and interests 2. Complex cross-border compliance	1. Sharing successful collaboration models 2. Analyzing key cross-border compliance considerations
Policy Environment	1. Progressive refinement of EU HTA regulations and related frameworks 2. Government support for innovative therapy R&D	1. Significant variations in regulatory implementation 2. Difficulty balancing innovation with patient safety	1. Dedicated sessions interpreting regulatory impacts 2. Gathering corporate feedback to refine policies

10. Appendix: Useful Resources, Additional Information, and Bio International Conference 2025 Reference Materials

10.1 Conference Contact Information

 For any inquiries or additional information regarding Nordic Life Science Day 2025, please contact the conference organizers via the following channels:

Table 10-1 Comparison of Official Conference Contact Channels

Contact Channel	Contact Method	Purpose	Response Time (Estimated)
Conference Website	https://nlsdays.com/	Registration, Agenda Search, Partner System Portal	Real-time (Self-service)
Email	info@nlsdays.com	Inquiries regarding registration, sponsorship, and partnerships	1-2 business days
Phone	+46 8 545 015 00	Urgent inquiries (e.g., registration issues)	Within 1-2 hours during business hours

10.2 Transportation Information

 Gothenburg is easily accessible from around the world.

Table 10-2 Comparison of Major Transportation Options in Gothenburg

Transportation Mode	Suitable Scenarios	Advantages	Considerations
Air Travel (Landvetter Airport)	International / Long-distance travel	Wide coverage, fast speed	Arrive at the airport 1.5-2 hours in advance to check in
Train (Central Station)	Within Sweden / Short Trips in Northern Europe (e.g., Stockholm)	Comfortable, punctual, scenic views	High-speed trains require advance booking to avoid standing room during peak seasons
Long-distance buses	Cross-city travel in Europe (e.g., Gothenburg – Oslo)	High value for money	Choose reputable companies (e.g., Flixbus) and confirm luggage allowances
Local buses (Västtrafik)	City commuting	Wide coverage, low fares	Download the Vasttrafik app to view real-time schedules
Ferries	Travel to Scandinavian Peninsula / European coastal cities	Vehicle transport available, ideal for leisure travel	Book ferry tickets in advance to confirm sailing times

10.3 Local Attractions and Cultural Activities

 During your stay in Gothenburg, we recommend exploring the city’s numerous attractions and cultural facilities:

Table 10-3 Recommended Gothenburg Attractions and Experience Comparison

Attraction Name	Type	Core Experience	Recommended Visit Duration	Suitable Audience
Libeberg Amusement Park	Entertainment	Thrill rides, seasonal activities	3–4 hours	Families, young adults
Göteborgs Operan	Culture	World-class opera and musical theater performances	2-3 hours (depending on performance length)	Culture enthusiasts
Space Science Center	Science education	Interactive exhibits, aquarium, rainforest experience	2-3 hours	Attendees with children, researchers
Haga District	Historic District	Historic buildings, boutiques, cafes	1-2 hours	Attendees who enjoy slow travel and shopping
Feskekorka (Fish Church)	Culinary Delights	Fresh seafood market in a unique church-like building	1 hour	Food enthusiasts, photography enthusiasts

10.4 Weather and Climate Information

 October in Gothenburg typically features cool weather with alternating sunny and cloudy days.

Table 10-4: Gothenburg October Weather and Dress Recommendations

Weather Indicator	October Average Data	Dress Recommendations	Notes
Highest Temperature	10-12°C (50-54°F)	Lightweight sweaters, shirts, and jackets	Large temperature difference between morning and evening; layered clothing recommended
Lowest Temperature	5-7°C (41-45°F)	Warm coat, scarf, thin gloves	Indoor heating is available; consider layering clothing for indoor and outdoor use
Precipitation	70-80mm (relatively humid)	Waterproof jacket, umbrella	Carry a compact umbrella to avoid getting caught in the rain outdoors
Weather Conditions	Alternating between sunny and cloudy	Wear dark-colored clothing for stain resistance, paired with bright-colored accessories	Check the weather forecast and adjust your travel plans accordingly

10.5 Emergency Contact Information

 In case of emergency during your stay in Gothenburg, use the following contacts:

•  Emergency services (police, fire, ambulance): 112
•  Non-emergency medical assistance: 1177
•  Your Country’s Embassy or Consulate: Contact information for your country’s diplomatic mission in Sweden can be found online.

10.6 Useful Apps and Resources for Traveling in Gothenburg

 To facilitate your travels during your stay in Gothenburg, we recommend the following practical apps and resources:

Table 10-5 Comparison of Gothenburg Transportation Tools

App/Resource Name	Function	Advantages	Use Cases
Vasttrafik App	Real-time local public transit schedules, route search, and ticket purchase	Official app with accurate information and direct ticket purchasing	Ride buses, trams, and other city public transportation
Google Maps	Navigation and route planning (walking / public transit / driving)	Global coverage with real-time traffic updates	Navigate from your hotel to the conference center and attractions
Uber/Bolt	Ride-Hailing Services	Convenient, transparent pricing, supports online payment	For late-night trips or when carrying bulky luggage
TripAdvisor	Attractions / Restaurant recommendations, user reviews	Authentic user feedback to help you filter quality experiences	Select restaurants and plan leisure activities

10.7 Currency and payment information

 Sweden uses the Swedish krona (SEK) as its currency.

Table 10-6 Currency and Payment Methods Comparison in Gothenburg

Payment Method	Usage Scenarios	Advantages	Considerations
Swedish Krona (SEK) Cash	Small purchases (e.g., convenience stores, food stalls)	No reliance on electronic devices	Exchange points are concentrated at airports and city centers; it is recommended to exchange only small amounts
Credit/Debit Cards	Most purchases (restaurants, hotels, shopping malls)	Convenient, secure, supports contactless payments	Ensure your card supports chip + PIN; some merchants do not accept magnetic stripe cards
Mobile payments (e.g., Apple Pay)	Chain restaurants, large shopping malls	No need to carry physical cards; fast payment speed	Ensure sufficient phone battery; some small merchants do not support

10.8 Local Food and Dining Recommendations

 Gothenburg’s culinary scene is vibrant and diverse, featuring fresh, locally sourced ingredients.

Table 10-7 Comparison of Gothenburg’s Signature Cuisine and Dining Scenarios

Cuisine Type	Representative Dishes	Recommended Experience Settings	Ideal Audience	Per-Person Cost (Estimated)
Traditional Swedish Cuisine	Swedish meatballs (kottbullar), Gravlax (cured salmon)	Traditional Swedish restaurants (e.g., near Aveny)	Attendees seeking to experience local culture	300-500 SEK
Seafood	Fresh fish, shellfish, crayfish	Feskekorka Fish Church, seaside restaurant	Seafood enthusiasts	400-600 SEK
Fika Culture	Cinnamon bun (kanelbulle), cardamom bun (kardemummabulle) + coffee	Local cafés (e.g., Haga district)	Casual hours, business networking	80-150 SEK
International cuisine	Italian cuisine, Asian cuisine	Downtown business district (e.g., Viking Street)	For attendees with diverse taste preferences	250-400 SEK